182 related articles for article (PubMed ID: 26630134)
1. Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms--Predictive and Prognostic Markers for Treatment Stratification.
Krug S; Boch M; Daniel H; Nimphius W; Müller D; Michl P; Rinke A; Gress TM
PLoS One; 2015; 10(12):e0143822. PubMed ID: 26630134
[TBL] [Abstract][Full Text] [Related]
2. Relevance of dihydropyrimidine-dehydrogenase and thymidylate-synthase in patients with pancreatic neuroendocrine neoplasms treated with 5-FU-based chemotherapy.
Krug S; Boch M; Nimphius W; Gress TM; Michl P; Rinke A
Pancreatology; 2017; 17(1):139-145. PubMed ID: 28027897
[TBL] [Abstract][Full Text] [Related]
3. Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors.
Mueller D; Krug S; Majumder M; Rinke A; Gress TM
BMC Cancer; 2016 Aug; 16():645. PubMed ID: 27538897
[TBL] [Abstract][Full Text] [Related]
4. Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours.
Dilz LM; Denecke T; Steffen IG; Prasad V; von Weikersthal LF; Pape UF; Wiedenmann B; Pavel M
Eur J Cancer; 2015 Jul; 51(10):1253-62. PubMed ID: 25935542
[TBL] [Abstract][Full Text] [Related]
5. Impact of Therapy Sequence with Alkylating Agents and MGMT Status in Patients with Advanced Neuroendocrine Tumors.
Krug S; Boch M; Rexin P; Gress TM; Michl P; Rinke A
Anticancer Res; 2017 May; 37(5):2491-2500. PubMed ID: 28476818
[TBL] [Abstract][Full Text] [Related]
6. Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy.
Shibuya H; Hijioka S; Sakamoto Y; Ito T; Ueda K; Komoto I; Kobayashi N; Kudo A; Yasuda H; Miyake H; Arita J; Kiritani S; Ikeda M; Imaoka H; Ueno M; Kobayashi S; Furuta M; Nagashio Y; Murohisa G; Aoki T; Matsumoto S; Motoya M; Azemoto N; Itakura J; Horiguchi S; Yogi T; Kawagoe T; Miyaoka Y; Imamura F; Senju M; Arioka H; Hara K; Imamura M; Okusaka T
Cancer Chemother Pharmacol; 2018 Oct; 82(4):661-668. PubMed ID: 30054710
[TBL] [Abstract][Full Text] [Related]
7. Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors.
Rogers JE; Lam M; Halperin DM; Dagohoy CG; Yao JC; Dasari A
Neuroendocrinology; 2022; 112(1):34-42. PubMed ID: 33434908
[TBL] [Abstract][Full Text] [Related]
8. Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity.
Clewemar Antonodimitrakis P; Sundin A; Wassberg C; Granberg D; Skogseid B; Eriksson B
Neuroendocrinology; 2016; 103(3-4):345-53. PubMed ID: 26279284
[TBL] [Abstract][Full Text] [Related]
9. Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy.
Lahner H; Mathew A; Klocker AL; Unger N; Theysohn J; Rekowski J; Jöckel KH; Theurer S; Schmid KW; Herrmann K; Führer D
Endocrine; 2022 Jan; 75(1):293-302. PubMed ID: 34480724
[TBL] [Abstract][Full Text] [Related]
10. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.
Gupta S; Johnson MM; Murthy R; Ahrar K; Wallace MJ; Madoff DC; McRae SE; Hicks ME; Rao S; Vauthey JN; Ajani JA; Yao JC
Cancer; 2005 Oct; 104(8):1590-602. PubMed ID: 16134179
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE).
Roquin G; Baudin E; Lombard-Bohas C; Cadiot G; Dominguez S; Guimbaud R; Niccoli P; Legoux JL; Mitry E; Rohmer V; Ruszniewski P; Walter T; Ducreux M; Couvelard A; Scoazec JY; Ramond-Roquin A; Caroli-Bosc FX; Hentic O
Neuroendocrinology; 2018; 106(1):38-46. PubMed ID: 28152531
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors.
Walter T; Bruneton D; Cassier PA; Hervieu V; Pilleul F; Scoazec JY; Chayvialle JA; Lombard-Bohas C
Clin Colorectal Cancer; 2010 Oct; 9(4):248-54. PubMed ID: 20920998
[TBL] [Abstract][Full Text] [Related]
13. Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan.
Aoki T; Kokudo N; Komoto I; Takaori K; Kimura W; Sano K; Takamoto T; Hashimoto T; Okusaka T; Morizane C; Ito T; Imamura M
J Gastroenterol; 2015 Jul; 50(7):769-75. PubMed ID: 25348496
[TBL] [Abstract][Full Text] [Related]
14. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)--a phase II non-randomised trial.
Ducreux M; Dahan L; Smith D; O'Toole D; Lepère C; Dromain C; Vilgrain V; Baudin E; Lombard-Bohas C; Scoazec JY; Seitz JF; Bitoun L; Koné S; Mitry E
Eur J Cancer; 2014 Dec; 50(18):3098-106. PubMed ID: 25454412
[TBL] [Abstract][Full Text] [Related]
16. The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors.
Krug S; Gress TM; Michl P; Rinke A
Digestion; 2017; 96(2):67-75. PubMed ID: 28728148
[TBL] [Abstract][Full Text] [Related]
17. Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors.
O'Toole D; Couvelard A; Rebours V; Zappa M; Hentic O; Hammel P; Levy P; Bedossa P; Raymond E; Ruszniewski P
Endocr Relat Cancer; 2010 Dec; 17(4):847-56. PubMed ID: 20570957
[TBL] [Abstract][Full Text] [Related]
18. Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases.
Hur S; Chung JW; Kim HC; Oh DY; Lee SH; Bang YJ; Kim WH
J Vasc Interv Radiol; 2013 Jul; 24(7):947-56; quiz 957. PubMed ID: 23602421
[TBL] [Abstract][Full Text] [Related]
19. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.
Sun W; Lipsitz S; Catalano P; Mailliard JA; Haller DG;
J Clin Oncol; 2005 Aug; 23(22):4897-904. PubMed ID: 16051944
[TBL] [Abstract][Full Text] [Related]
20. Combination of weekly streptozocin and oral S-1 treatment for patients of unresectable or metastatic pancreatic neuroendocrine neoplasms.
Ono H; Kudo A; Akahoshi K; Ogura T; Ogawa K; Ban D; Tanaka S; Tanabe M
J Cancer Res Clin Oncol; 2020 Mar; 146(3):793-799. PubMed ID: 31844980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
